Gain Therapeutics Ownership
| GANX Stock | USD 1.68 0.06 3.70% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 27.1 M | Current Value 28.7 M | Avarage Shares Outstanding 11.9 M | Quarterly Volatility 6.6 M |
Gain Stock Ownership Analysis
The company recorded a loss per share of 0.83. Gain Therapeutics had not issued any dividends in recent years. Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. The company was founded in 2017 and is based in Bethesda, Maryland. Gain Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. To learn more about Gain Therapeutics call LLM IUR at 301 500 1556 or check out https://gaintherapeutics.com.Gain Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Gain Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gain Therapeutics backward and forwards among themselves. Gain Therapeutics' institutional investor refers to the entity that pools money to purchase Gain Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cambridge Invest Research Advisors, Inc. | 2025-03-31 | 59.5 K | Kovitz Investment Group Partners, Llc | 2025-03-31 | 47.6 K | Ubs Group Ag | 2025-03-31 | 43.4 K | Springbok Capital Management, Llc | 2025-03-31 | 35.8 K | Bridgeway Capital Management, Llc | 2025-03-31 | 30 K | Quadrature Capital Llp | 2025-03-31 | 20.2 K | Citadel Advisors Llc | 2025-03-31 | 19 K | Benedict Financial Advisors, Inc. | 2025-03-31 | 18 K | Sandhill Capital Partners Llc | 2025-03-31 | 15.4 K | Jones Financial Companies Lllp | 2025-03-31 | 427.7 K | Geode Capital Management, Llc | 2025-03-31 | 282.2 K |
Gain Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gain Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gain Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gain Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gain Therapeutics Outstanding Bonds
Gain Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gain Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gain bonds can be classified according to their maturity, which is the date when Gain Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| HLNLN 3625 24 MAR 32 Corp BondUS36264FAM32 | View | |
| HLNLN 3375 24 MAR 29 Corp BondUS36264FAL58 | View | |
| HLNLN 4 24 MAR 52 Corp BondUS36264FAN15 | View | |
| HLNLN 3375 24 MAR 27 Corp BondUS36264FAK75 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| US36261NAA54 Corp BondUS36261NAA54 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.